Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

被引:751
作者
Ogilvie, Isla M. [1 ]
Newton, Nick [1 ]
Welner, Sharon A. [1 ]
Cowell, Warren [2 ]
Lip, Gregory Y. H. [3 ]
机构
[1] BioMedCom Consultants Inc, Montreal, PQ H9P 2V9, Canada
[2] Bayer HealthCare, Global Hlth Econ & Reimbursement, Uxbridge, Middx, England
[3] Univ Birmingham Ctr Cardiovasc Sci, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England
关键词
Atrial fibrillation; Current treatment practices; Guidelines; Oral anticoagulant therapy; Stroke risk; STROKE PREVENTION; RISK-FACTORS; WARFARIN USE; ANTITHROMBOTIC THERAPY; ISCHEMIC-STROKE; MEDICARE BENEFICIARIES; PROSPECTIVE COHORT; PREDICTING STROKE; PREVALENCE; MANAGEMENT;
D O I
10.1016/j.amjmed.2009.11.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Atrial fibrillation is associated with substantial mortality and morbidity from stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin), atrial fibrillation patients at high risk for stroke are often under-treated. This systematic review compares current treatment practices for stroke prevention in atrial fibrillation with published guidelines. METHODS: Literature searches (1997-2008) identified 98 studies concerning current treatment practices for stroke prevention in atrial fibrillation. The percentage of patients eligible for oral anticoagulation due to elevated stroke risk was compared with the percentage treated. Under-treatment was defined as treatment of <70% of high-risk patients. RESULTS: Of 54 studies that reported stroke risk levels and the percentage of patients treated, most showed underuse of oral anticoagulants for high-risk patients. From 29 studies of patients with prior stroke/transient ischemic attack who should all receive oral anticoagulation according to published guidelines, 25 studies reported under-treatment, with 21 of 29 studies reporting oral anticoagulation treatment levels below 60% (range 19%-81.3%). Subjects with a CHADS(2) (congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score >= 2 also were suboptimally treated, with 7 of 9 studies reporting treatment levels below 70% (range 39%-92.3%). Studies (21 of 54) using other stroke risk stratification schemes differ in the criteria they use to designate patients as "high risk," such that direct comparison is not possible. CONCLUSIONS: This systematic review demonstrates the underuse of oral anticoagulation therapy for real-world atrial fibrillation patients with an elevated risk of stroke, highlighting the need for improved therapies for stroke prevention in atrial fibrillation. (C) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 638-645
引用
收藏
页码:638 / U86
页数:12
相关论文
共 78 条
  • [1] Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: A prospective, observational study
    Ageno W.
    Ambrosini F.
    Nardo B.
    Imperiale D.
    Dentali F.
    Mera V.
    Cattaneo R.
    Barlocco E.
    Steidl L.
    Venco A.
    [J]. Journal of Thrombosis and Thrombolysis, 2001, 12 (3) : 225 - 230
  • [2] Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants - Results from a Danish quality-control registry of 22 179 patients with ischemic stroke
    Andersen, Klaus Kaae
    Olsen, Tom Skyhoj
    [J]. STROKE, 2007, 38 (02) : 259 - 263
  • [3] 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation
    Anderson, N.
    Fuller, R.
    Dudley, N.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2007, 100 (05) : 263 - 269
  • [4] [Anonymous], 2001, CIRCULATION, V104, P2118
  • [5] [Anonymous], 36 NICE
  • [6] [Anonymous], STROB STAT CHECKL IT
  • [7] Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?
    Baruch, Lawrence
    Gage, Brian F.
    Horrow, Jay
    Juul-Moller, Steen
    Labovitz, Arthur
    Persson, Maria
    Zabalgoitia, Miguel
    [J]. STROKE, 2007, 38 (09) : 2459 - 2463
  • [8] Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up
    Benetos, Athanase
    Pannier, Bruno
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (4-5): : 791 - 803
  • [9] Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation
    Birman-Deych, E
    Radford, MJ
    Nilasena, DS
    Gage, BF
    [J]. STROKE, 2006, 37 (04) : 1070 - 1074
  • [10] Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study
    Bo, Simona
    Valpreda, Susanna
    Scaglione, Luca
    Boscolo, Daniela
    Piobbici, Marina
    Bo, Mario
    Ciccone, Giovannino
    [J]. BMC PUBLIC HEALTH, 2007, 7 (1)